Insmed Showcases Commitment to Pulmonary Disease Treatment at ATS 2026 Conference with Key Research Findings

Insmed Incorporated demonstrates a strong commitment to advancing treatment for pulmonary diseases, as evidenced by its participation in the upcoming American Thoracic Society International Conference 2026 (ATS 2026). The company plans to present six abstracts during the conference, highlighting critical research including late-breaking data from the Phase 3b ENCORE study on ARIKAYCE® (amikacin liposome inhalation suspension). This study focuses on adult patients newly diagnosed with Mycobacterium avium complex lung infections and contrasts the efficacy of ARIKAYCE combined with a multidrug therapy regimen against a placebo. Insmed aims to showcase these findings to emphasize the potential for earlier interventions in treatment pathways for impacted patients.

In addition to the insights on ARIKAYCE, Insmed also shares exciting updates regarding its other investigational therapies at ATS 2026. A post-hoc analysis from the Phase 3 ASPEN trial will be presented, examining how BRINSUPRI® (brensocatib) affects symptoms in patients with non-cystic fibrosis bronchiectasis. Moreover, the company will reveal pharmacokinetic data regarding treprostinil palmitil inhalation powder (TPIP), delving into the disease burden associated with pulmonary hypertension linked to interstitial lung disease. These presentations underscore Insmed's focus on understanding both the therapeutic impact and the broader implications of pulmonary conditions.

Martina Flammer, M.D., Chief Medical Officer of Insmed, highlights that the company is dedicated to improving the landscape of treatments for patients suffering from severe pulmonary conditions. Insmed not only embraces these research opportunities but also takes active steps to enrich the scientific community. The company is providing an independent research grant to support ATS in an initiative aimed at enhancing bronchiectasis diagnosis in the U.S., which intends to tackle underdiagnosis rates by pinpointing patients who may have been misdiagnosed with asthma or COPD. Through its engagement at the conference and the establishment of meaningful partnerships, Insmed continues to bolster efforts towards better health outcomes for patients afflicted with complex pulmonary diseases.

Insmed's proactive approach at ATS 2026 illustrates its strategic vision to emerge as a leader in the treatment of severe pulmonary conditions. By prioritizing substantial research and encouraging collaboration within the healthcare community, the company is fostering a more informed environment for both clinicians and patients, ensuring they have access to the latest advancements in pulmonary medicine.